Amina Zoubeidi

Associate Professor, Department of Urologic Sciences
Degrees / Designations 

University Mohamed V, Morocco BSc 1990-1994 Biology University. du Quebec, Montreal MSc 1995-1998 Biology University of Montreal PhD 1998-2004 Biochemistry 2003 - 2004 Post-doctoral Fellow, McGill University, Montreal 2005 - 2009 Post-doctoral Fellow, Vancouver Prostate Centre 2009 - Research Scientist, Vancouver Prostate Centre (as of July 1, 2014)  - Associate Professor, Dept. of Urologic Sciences, University of British Columbia

(604) 875-4111 # 68880
Mailing Address 
2660 Oak Street Vancouver BC V6H 3Z6, Canada


Academic Appointment 
Associate Professor
Body Locations and Systems 
Kidneys and Urinary System
Disorders and Conditions 

Dr Zoubeidi major research focus is to uncover molecular mechanisms of prostate cancer progression to the castrate-resistant stage and metastatic disease with a special interest on elucidating mechanisms of epithelial mesenchymal transition. She elucidates diverse mechanisms involving stress activated proteins, Hsp27, clusterin, and tyrosine kinases Lyn and Fer in androgen independent progression. She recently developed pre-clinical models of MDV3100 resistant tumors and cell lines and studying mechanisms of resistance to MDV3100. She has an extensive expertise in cell signaling, molecular and cellular biology and in vivo efficacy studies. She holds a Michel Smith Foundation for Health Research, Career development award (2012-2021), a merit award for academic achievement, University of British Columbia (2011), the New Investigator Award, Terry Fox Research Institute (2010-2014),a new Investigator Award, Prostate Cancer Foundation (USA) (2010-2013), and multiple research context awards including first prize, Research award, American Urological Association (2008), first prize, Research award, Northwest Urological Society (2007) and AACR- Brigid G. Leventhal Scholar in Cancer Research Award (2007) and a dean’s honor list, PhD thesis, Université de Montréal (2005) among others.

Current Projects 

My research program aims at uncovering how androgen receptor activity controls phenotypic plasticity, which has been associated with the clinically relevant problem of drug resistance in prostate cancer (PCa). Resistance to newly developed androgen receptor pathway inhibitors (ARPIs), rapidly emerges and patients generally die within two years. In particular, a subset of patients who relapse following ARPI therapy exhibit lineage switching whereby tumours shed their dependence on AR signaling and emerge with neuroendocrine features. These tumours, termed treatment induced neuroendocrine prostate cancer (t-NEPC), carry an extremely poor prognosis and, to date, treatment remains decades old cytotoxic chemotherapy which carries a short-lived response at the cost of significant toxicity. As a critical tool in my arsenal to investigate the highly clinically relevant problem of treatment resistance to anti-androgens, I have developed a unique set of reagents and resources, including tumours and cell lines resistant to Enzalutamide, that make me highly competitive globally in this field of research. Using this model, we discovered BRN2 as a major driver of ENZ resistance and NEPC and developed small molecule inhibitors for BRN2. For translational importance, my research group has uncovered mechanisms of cell plasticity and treatment resistance, and designed combination therapies that have guided clinical trials in CRPC including therapeutic combinations of AKT inhibitors with Enz.